Innooqi Biomedicine

Innooqi Biomedicine is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of innovative biological therapies for oncology and metabolic diseases. The company's lead candidate, IUAb190708, is a monoclonal antibody targeting PD-L1 that is currently undergoing Phase 1 clinical evaluation for the treatment of advanced or recurrent solid tumors, including colorectal and biliary tract cancers. Innooqi operates research and development facilities in Suzhou and Shanghai, utilizing a proprietary platform for antibody engineering. The company was rebranded from Fenghong biomedical technology (Kunshan) Co., Ltd. to focus on its expanding pipeline of immunotherapy and metabolic drug candidates.